Clinical Trials | October 13, 2025
Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
Merck will showcase results in innovative solutions in HIV treatment and prevention
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
SkinMedica redefines luxury skincare with reimagined packaging and new HA5 hydra collagen water burst moisturizer
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
Subscribe To Our Newsletter & Stay Updated
